Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).
复制标题
DOI：
10.1016/j.ejca.2020.09.035
复制
发表时间：
2020-12
期刊：
影响因子：
--
通讯作者：
GCO-002 CACOVID-19 collaborators/investigators
中科院分区：
文献类型：
--
作者：
Lièvre A;Turpin A;Ray-Coquard I;Le Malicot K;Thariat J;Ahle G;Neuzillet C;Paoletti X;Bouché O;Aldabbagh K;Michel P;Debieuvre D;Canellas A;Wislez M;Laurent L;Mabro M;Colle R;Hardy-Bessard AC;Mansi L;Colomba E;Bourhis J;Gorphe P;Pointreau Y;Idbaih A;Ursu R;Di Stefano AL;Zalcman G;Aparicio T;GCO-002 CACOVID-19 collaborators/investigators
癌症患者被认为患上严重的2019冠状病毒病（COVID-19）感染和死于该疾病的风险增加。在这项工作中，研究了癌症患者COVID-19严重程度和死亡率的预测因素。在这项大型的全国性回顾性前瞻性队列研究中，我们收集了2020年3月1日至6月11日期间确诊的实体瘤和COVID-19患者的数据。主要终点是全因死亡率，COVID-19严重程度（定义为入住重症监护室（ICU）和/或机械通气和/或死亡）是次要终点之一。从2020年4月4日至6月11日，分析了1289例患者。最常见的癌症是消化道和胸部癌症。总共有424名（33%）患者患有严重的COVID-19，370名（29%）患者死亡。在多因素分析中，与死亡相关的独立因素是男性（比值比1.73，95%CI：1.18-2.52），美国东部肿瘤协作组体能量表（ECOG PS）≥ 2（OR 3.23，95%CI：2.27-4.61）、更新的Charlson合并症指数（OR 1.08，95%CI：1.01-1.16）和入住ICU（OR 3.62，95%CI 2.14-6.11）。同样的因素，COVID-19诊断前的年龄沿着皮质类固醇，以及胸部原发肿瘤部位与COVID-19严重程度独立相关。除了在可检测到严重急性呼吸综合征冠状病毒2型的患者亚组中使用细胞毒性化疗外，在过去3个月内给予的抗癌治疗对死亡率或COVID-19严重程度没有任何影响（SARS-CoV-2）的逆转录聚合酶链反应（RT-PCR），这与死亡风险的轻微增加有关（OR 1.53; 95%CI：1.00-2.34; p = 0.05）。共有431名（39%）患者在确诊COVID-19后中断或停止了全身抗癌治疗（如化疗、靶向或免疫治疗）。癌症患者的死亡率和COVID-19严重程度较高，且与患者的一般特征相关。我们发现，除了在RT-PCR证实的患者亚组中使用细胞毒化疗外，近期的抗癌治疗没有不良影响。在近40%的患者中，在COVID-19诊断后中断或停止了全身抗癌治疗。
Cancer patients are thought to have an increased risk of developing severe Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, predictive factors for COVID-19 severity and mortality in cancer patients were investigated. In this large nationwide retro-prospective cohort study, we collected data on patients with solid tumours and COVID-19 diagnosed between March 1 and 11th June 2020. The primary end-point was all-cause mortality and COVID-19 severity, defined as admission to an intensive care unit (ICU) and/or mechanical ventilation and/or death, was one of the secondary end-points. From April 4 to 11th June 2020, 1289 patients were analysed. The most frequent cancers were digestive and thoracic. Altogether, 424 (33%) patients had a severe form of COVID-19 and 370 (29%) patients died. In multivariate analysis, independent factors associated with death were male sex (odds ratio 1.73, 95%CI: 1.18–2.52), The Eastern Cooperative Oncology Group Performance Scale (ECOG PS) ≥ 2 (OR 3.23, 95%CI: 2.27–4.61), updated Charlson comorbidity index (OR 1.08, 95%CI: 1.01–1.16) and admission to ICU (OR 3.62, 95%CI 2.14–6.11). The same factors, age along with corticosteroids before COVID-19 diagnosis, and thoracic primary tumour site were independently associated with COVID-19 severity. None of the anticancer treatments administered within the previous 3 months had any effect on mortality or COVID-19 severity, except for cytotoxic chemotherapy in the subgroup of patients with detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by reverse transcriptase polymerase chain reaction (RT-PCR), which was associated with a slight increase of the risk of death (OR 1.53; 95%CI: 1.00–2.34; p = 0.05). A total of 431 (39%) patients had their systemic anticancer treatment (such as chemotherapy, targeted or immune therapy) interrupted or stopped following diagnosis of COVID-19. Mortality and COVID-19 severity in cancer patients are high and are associated with general characteristics of patients. We found no deleterious effects of recent anticancer treatments, except for cytotoxic chemotherapy in the RT-PCR-confirmed subgroup of patients. In almost 40% of patients, the systemic anticancer therapy was interrupted or stopped after COVID-19 diagnosis.
登录
查看更多内容
影响因子：
82.9
作者：
Robilotti EV;Babady NE;Mead PA;Rolling T;Perez-Johnston R;Bernardes M;Bogler Y;Caldararo M;Figueroa CJ;Glickman MS;Joanow A;Kaltsas A;Lee YJ;Lucca A;Mariano A;Morjaria S;Nawar T;Papanicolaou GA;Predmore J;Redelman-Sidi G;Schmidt E;Seo SK;Sepkowitz K;Shah MK;Wolchok JD;Hohl TM;Taur Y;Kamboj M
通讯作者：
Kamboj M
COVID-19感染的癌症患者的临床特征：中国武汉市三家医院的回顾性病例研究
影响因子：
50.5
作者：
Zhang, L.;Zhu, F.;Zhou, M.
通讯作者：
Zhou, M.
影响因子：
51.1
作者：
Garassino, Marina Chiara;Whisenant, Jennifer G.;Horn, Leora
通讯作者：
Horn, Leora
影响因子：
28.2
作者：
Dai, Mengyuan;Liu, Dianbo;Cai, Hongbing
通讯作者：
Cai, Hongbing
影响因子：
6.2
作者：
Zhang, Hongyan;Wang, Linwei;Yu, Yi
通讯作者：
Yu, Yi